Achieving goal glycosylated hemoglobin levels in type 2 diabetes mellitus: Practical strategies for success with insulin therapy

Insulin

Volumn 1, Issue 3, 2006, Pages 109-121

  Garg, Satish K ^a   Ulrich, Heather ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

continuous subcutaneous insulin pump therapy; glycemic control; glycosylated hemoglobin; insulin analogues; postprandial hyperglycemia; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; RECOMBINANT DNA; SULFONYLUREA DERIVATIVE;

ARTICLE; BOLUS INJECTION; CELL FUNCTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC MICROANGIOPATHY; DIET THERAPY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MIXTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN PUMP; INSULIN RELEASE; INSULIN TREATMENT; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT MONITORING; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

EID: 33748754719     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80020-5     Document Type: Article

References (85)

1. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
2. Available at. Centers for Disease Control and Prevention. National Diabetes Fact Sheet. Accessed May 5, 2005 (2003), US Dept of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Go. http://www.cdc.gov/diabetes/pubs/factsheet.htm
3. Available at:. American Diabetes Association. National Diabetes Fact Sheet. Accessed January 26, 2006. http://www.cdc.gov/diabetes/pubs/factsheet05.htm
4. [published correction appears in Diabetes. 1996;45:1655]. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 44 (1995) 1249-1258
5. Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1 (1978) 168-188
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
7. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
8. Shichiri M., Kishikawa H., Ohkubo Y., and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2 (2000) B21-B29
9. [published correction appears in N Engl J Med. 2000;342:1376]. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 342 (2000) 381-389
10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 (2003) 2159-2167
11. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353 (2005) 2643-2653
12. Hirsch I.B., and Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J Diabetes Complications 19 (2005) 178-181
13. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 Suppl 1 (2006) S4-S42
14. American Association of Clinical Endocrinologists, and American College of Endocrinology. Medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self- management-2002 update. Endocr Proct. 8 Suppl 1 (2002) 40-82
15. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med. 16 (1999) 716-730
16. In: Leahy J.L., and Cefalu W.T. (Eds). Insulin Therapy (2002), Marcel Dekker, Inc, New York, NY
17. Orlando, Fla. Abstract 603. Rave K., Nosek L., Heinemann L., et al. Insulin glulisine: Pharmacokinetic (PK) and pharmacodynamic (PD) properties in comparison with insulin lispro and regular human insulin in Japanese and Caucasian volunteers. Presented at: American Diabetes Association 64th Scientific Sessions (June 4-8, 2004)
18. Orlando, Fla. Abstract 2350. Burger F., Scholtz H., Frick A., and Becke R.H.A. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine (GLU) versus insulin lispro (IL) and regular human insulin (RHI) in patients with type 1 diabetes. Presented at: American Diabetes Association 64th Scientific Sessions (June 4-8, 2004)
19. Heinemann L., Sinha K., Weyer C., et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med. 16 (1999) 332-338
20. Pieber T.R., Plank J., Goerzer E., et al. Duration of action, pharmacodynamic profile and between subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 51 Suppl 2 (2002) A53
21. Feher M.D., and Bailey C.J. Reclassifying insulins. Br J Diabetes Vasc Dis. 4 (2004) 39-42
22. Cook D.L., and TaborskyJr G.J. β-cell function and insulin secretion. In: Porte D., and Sherwin R.S. (Eds). Ellenberg and Rifkins Diabetes Mellitus. 5th ed (1997), Lippincott-Raven, Philadelphia, Pa 49-73
23. Rossetti L., Giaccari A., and DeFronzo R.A. Glucose toxicity. Diabetes Care 13 (1990) 610-630
24. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: The epidemiological evidence. Diabetologia 44 (2001) 2107-2114
25. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with in creasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
26. Overmann H., and Heinemann L. Injection-meal interval: Recommendations of diabetologists and how patients handle it. Diabetes Res Clin Proct. 43 (1999) 137-142
27. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23 (2000) 644-649
28. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000) 2142-2148
29. Garg S.K., Ellis S., and Ulrich H. Insulin glulisine: A new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Phormocother 6 (2005) 643-651
30. New Orleans, La. Abstract 471-P. Becker R.H.A., Frick A., Wessels D., and Scholtz H. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine. Presented at: American Diabetes Association 63rd Scientific Sessions (June 3-17, 2003)
31. Howey D.C., Bowsher R.R., Brunelle R.L., and Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43 (1994) 396-402
32. Garg S.K., Anderson J.H., Perry S.V., et al. Long-term efficacy of humalog in subjects with type 1 diabetes mellitus. Diabet Med 16 (1999) 384-387
33. Anderson Jr. J.H., Brunelle R.L., Koivisto V.A., et al., Multicenter Insulin Lispro Study Group. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 46 (1997) 265-270
34. Home P.D., Lindholm A., Hylleberg B., Round P., and UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: A multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21 (1998) 1904-1909
35. Brunelle B.L., Llewelyn J., Anderson Jr. J.H., et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21 (1998) 1726-1731
36. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 165 (2005) 1337-1344
37. Torlone E., Pampanelli S., Lalli C., et al. Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19 (1996) 945-952
38. Lindholm A., McEwen J., and Riis A.P. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22 (1999) 801-805
39. Rutledge K.S., Chase H.P., Klingensmith G.J., et al. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 100 (1997) 968-972
40. [published cor rection appears in Endocr Proct. 2005;11:145]. Garg S.K., Rosenstock J., and Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: Insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Proct. 11 (2005) 11-17
41. Raskin P., Klaff L., Bergenstal R., et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 (2000) 1666-1671
42. Rossetti P., Pampanelli S., Fanelli C., et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapidacting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26 (2003) 1490-1496
43. Rosenstock J., Schwartz S.L., Clark Jr. C.M., et al. Basal insulin therapy in type 2 diabetes: 28-Week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24 (2001) 631-636
44. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28 (2005) 950-955
45. Garg S.K., Gottlieb P.A., Hisatomi M.E., et al. Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Proct 66 (2004) 49-56
46. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
47. Hamann A., Matthaei S., Rosak C., Silvestre L., and HOE901 / 4007 Study Group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 26 (2003) 1738-1744
48. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: The pharmacology of insulin detemir. Int J Obes Relat Metob Disord 28 Suppl 2 (2004) S23-S28
49. Heise T., Nosek L., Ronn R.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 (2004) 1614-1620
50. Orlando, Fla. Abstract 440-P. Hermansen K., Olsen K., Draeger E., et al. Significant reduction in blood glucose variability with insulin detemir versus NPH insulin: Confirmed by meta-analysis of continuous glucose monitoring. Presented at: American Diabetes Association 64th Scientific Sessions (June 4-8, 2004)
51. Home P., Bartley P., Russell-Jones D., et al., Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety, and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
52. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
53. De Leeuw I., Vague P., Selam J.L., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metob 7 (2005) 73-82
54. Hermansen K., Madsbad S., Perrild H., et al. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24 (2001) 296-301
55. Bode B.W., Tamborlane W.V., and Davidson P.C. Insulin pump therapy in the 21 st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 111 (2002) 69-77
56. Scheiner G., and Boyer B.A. Characteristics of basal insulin requirements by age and gender in type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Proct. 69 (2005) 14-21
57. Chase H.P., Saib S.Z., MacKenzie T., et al. Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. Diabet Med. 19 (2002) 317-321
58. Garg S.K., Anderson J.H., Gerard L.A., et al. Impact of insulin lispro on HbAl c values in insulin pump users. Diabetes Obes Metob. 2 (2000) 307-311
59. [published correction appears in Diabetes. 1997;46:1239]. Zinman B., Tildesley H., Chiasson J.L., et al. Insulin lispro in CSII: Results of a double-blind crossover study. Diabetes 46 (1997) 440-443
60. Renner R., Pfutzner A., Trautmann M., et al., German Humalog-CSII Study Group. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. Diabetes Care 22 (1999) 784-788
61. Raskin P., Holcombe J.H., Tamborlane W.V., et al. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 15 (2001) 295-300
62. Nathan D.M., Lou P., and Avruch J. Intensive conventional and insulin pump therapies in adult type 1 diabetes. A crossover study. Ann Intern Med 97 (1982) 31-36
63. Rudolph J.W., and Hirsch I.B. Assessment of therapy with continuous subcutaneous insulin infusion therapy in an academic diabetes clinic. Endocr Proct. 8 (2002) 401-405
64. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18 (1995) 361-376
65. Bode B.W., Steed R.D., and Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19 (1996) 324-327
66. Garg S.K., Walker A.J., Hoff H.K., et al. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 6 (2004) 9-15
67. Guinn T.S., Bailey G.J., and Mecklenburg R.S. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care 11 (1988) 46-51
68. Schade D.S., and Valentine V. To pump or not to pump. Diabetes Care. 25 (2002) 2100-2102
69. Hirsch I.B., Bode B.W., Garg S., et al., Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily insulin injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 28 (2005) 533-538
70. Rhoads G.G., Orsini L.S., Crown W., et al. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 47 (2005) 447-452
71. Zhang Q., and Menditto L. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample. Am J Ther. 12 (2005) 337-343
72. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
73. Raskin P., Allen E., Hollander P., et al., INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
74. Dahl Jorgensen K., Brinchmann-Hansen O., Hanssen K.F., et al. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: The Oslo Study. Br Med J (Clin Res Ed) 290 (1985) 811-815
75. [published correction appears in Arch Ophtholmol. 1998;116:1469]. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophtholmol 116 (1998) 874-886
76. Heisler M., Vijan S., Anderson R.M., et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make?. J Gen Intern Med 18 (2003) 893-902
77. Berger M., Jorgens V., and Muhlhauser I. Rationale for the use of insulin therapy alone as the pharmacological treatment of type 2 diabetes. Diabetes Care 22 Suppl 3 (1999) C71-C75
78. [published correction appears in Diabetes Care. 2002;25:1268]. Wright A., Burden A.C., Paisey R.B., et al., UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25 (2002) 330-336
79. Schiel R. Continuous subcutaneous insulin infusion in patients with diabetes mellitus. Ther Apher Dial 7 (2003) 232-237
80. Raskin P., Bode B.W., Marks J.B., et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel-group, 24-week study. Diabetes Care 26 (2003) 2598-2603
81. Garg S.K., Schwartz S., and Edelman S.V. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care 27 (2004) 734-738
82. Chase H.P., Kim L.M., Owen S.L., et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics 107 (2001) 222-226
83. Kerr D. Continuous blood glucose monitoring: Detection and prevention of hypoglycaemia. Int J Clin Proct Suppl. 123 (2001) 43-46
84. Garg S., Zisser H., Schwartz S., et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: A randomized controlled trial. Diabetes Care 29 (2006) 44-50
85. Tamada J.A., Garg S., Jovanovic L., et al., Cygnus Research Team. Noninvasive glucose monitoring: Comprehensive clinical results. JAMA 282 (1999) 1839-1844